P25α/TPPP expression increases plasma membrane presentation of the dopamine transporter and enhances cellular sensitivity to dopamine toxicity

FEBS Journal

Volumn 278, Issue 3, 2011, Pages 493-505

  Fjorback, Anja W ^a,b   Sundbye, Sabrina ^b   Justus C Dachsel ^b,c   Sinning, Steffen ^b   Wiborg, Ove ^a   Jensen, Poul H ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c MAYO CLINIC   (United States)

Author keywords

dopamine transporter; p25 ; Parkinsons disease; toxicity; TPPP; tubulin polymerization promoting protein

Indexed keywords

DOPAMINE TRANSPORTER; PROTEIN P25; PROTEIN P25 ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL ACTIVITY; CELL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL MEMBRANE; CELLS, CULTURED; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MICROSCOPY, FLUORESCENCE; NERVE TISSUE PROTEINS; PARKINSON DISEASE;

EID: 78751677886     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07970.x     Document Type: Article

References (41)

1. Fearnley JM, &, Lees AJ, (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283-2301.
2. Hirsch E, Graybiel AM, &, Agid YA, (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
3. Jenner P, &, Olanow CW, (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47, S161-S170.
4. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, &, Hong JS, (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20, 6309-6316.
5. Olanow CW, Jenner P, &, Brooks D, (1998) Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44, S167-S174. (Pubitemid 28423845)
6. Smith LA, Jackson MJ, Al Barghouthy G, Rose S, Kuoppamaki M, Olanow W, &, Jenner P, (2005) Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 20, 306-314. (Pubitemid 40613291)
7. Vergo S, Johansen JL, Leist M, &, Lotharius J, (2007) Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res 1185, 18-32.
8. Zheng G, Dwoskin LP, &, Crooks PA, (2006) Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J 8, E682-E692.
9. Goedert M, Spillantini MG, &, Davies SW, (1998) Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 8, 619-632.
10. Wersinger C, Prou D, Vernier P, &, Sidhu A, (2003) Modulation of dopamine transporter function by α-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J 17, 2151-2153.
11. Wersinger C, &, Sidhu A, (2003) Attenuation of dopamine transporter activity by α-synuclein. Neurosci Lett 340, 189-192.
12. Song YJ, Lundvig DM, Huang Y, Gai WP, Blumbergs PC, Hojrup P, Otzen D, Halliday GM, &, Jensen PH, (2007) p25α relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 171, 1291-1303.
13. Hlavanda E, Kovacs J, Olah J, Orosz F, Medzihradszky KF, &, Ovadi J, (2002) Brain-specific p25 protein binds to tubulin and microtubules and induces aberrant microtubule assemblies at substoichiometric concentrations. Biochemistry 41, 8657-8664.
14. Baker KG, Huang Y, McCann H, Gai WP, Jensen PH, &, Halliday GM, (2006) P25α immunoreactive but α-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol 111, 193-195.
15. Jellinger KA, (2006) P25α immunoreactivity in multiple system atrophy and Parkinson disease. Acta Neuropathol 112, 112.
16. Lindersson E, Lundvig D, Petersen C, Madsen P, Nyengaard JR, Hojrup P, Moos T, Otzen D, Gai WP, Blumbergs PC, et al. (2005) p25α stimulates α- synuclein aggregation and is co-localized with aggregated α-synuclein in α-synucleinopathies. J Biol Chem 280, 5703-5715.
17. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, Richter-Landsberg C, &, Jensen PH, (2009) α-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284, 10211-10222.
18. Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, Quan N, Stephens RL, Hill ER, Nottoli T, et al. (2006) Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci USA 103, 9333-9338.
19. Otzen DE, Lundvig DM, Wimmer R, Nielsen LH, Pedersen JR, &, Jensen PH, (2005) p25α is flexible but natively folded and binds tubulin with oligomeric stoichiometry. Protein Sci 14, 1396-1409.
20. Aramini JM, Rossi P, Shastry R, Nwosu C, Cunningham K, Xiao R, Liu J, Baran MC, Rajan PK, Acton TB, et al. (2008) Solution NMR structure of tubulin polymerization-promoting protein family member 3 from Homo sapiens. Accessed September 16 2008.
21. Kobayashi N, Koshiba S, Inoue M, Kigawa T, &, Yokoyama S, (2005) Solution structure of mouse CGI-38 protein.
22. 13C assignments for the 21 kDa Caenorhabditis elegans homologue of 'brain-specific' protein. J Biomol NMR 28, 91-92.
23. Wersinger C, Jeannotte A, &, Sidhu A, (2006) Attenuation of the norepinephrine transporter activity and trafficking via interactions with α-synuclein. Eur J Neurosci 24, 3141-3152.
24. Wersinger C, Rusnak M, &, Sidhu A, (2006) Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein. Eur J Neurosci 24, 55-64.
25. Jensen PH, Nielsen MS, Jakes R, Dotti CG, &, Goedert M, (1998) Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 273, 26292-26294.
26. Lotharius J, &, Brundin P, (2002) Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11, 2395-2407.
27. Langston JW, (1989) Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise. Mov Disord 4, S15-S25.
28. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, &, Uhl GR, (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94, 9938-9943.
29. Kovács GG, László L, Kovács J, Jensen PH, Lindersson E, Botond G, Molnár T, Perczel A, Hudecz F, Mezo G, et al. (2004) Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. Neurobiol Dis 17, 155-162.
30. Kovács GG, Gelpi E, Lehotzky A, Höftberger R, Erdei A, Budka H, &, Ovádi J, (2007) The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathol 113, 153-161.
31. Skjoerringe T, Lundvig DM, Jensen PH, &, Moos T, (2006) P25α/Tubulin polymerization promoting protein expression by myelinating oligodendrocytes of the developing rat brain. J Neurochem 99, 333-342.
32. Acevedo K, Li R, Soo P, Suryadinata R, Sarcevic B, Valova VA, Graham ME, Robinson PJ, &, Bernard O, (2007) The phosphorylation of p25/TPPP by LIM kinase 1 inhibits its ability to assemble microtubules. Exp Cell Res 313, 4091-4106.
33. Wersinger C, Vernier P, &, Sidhu A, (2004) Trypsin disrupts the trafficking of the human dopamine transporter by α-synuclein and its A30P mutant. Biochemistry 43, 1242-1253.
34. Wersinger C, &, Sidhu A, (2005) Disruption of the interaction of α-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 44, 13612-13624.
35. Vincze O, Tökési N, Oláh J, Hlavanda E, Zotter A, Horváth I, Lehotzky A, Tirián L, Medzihradszky KF, Kovács J, et al. (2006) Tubulin polymerization promoting proteins (TPPPs): members of a new family with distinct structures and functions. Biochemistry 45, 13818-13826.
36. Gu HH, Ahn J, Caplan MJ, Blakely RD, Levey AI, &, Rudnick G, (1996) Cell-specific sorting of biogenic amine transporters expressed in epithelial cells. J Biol Chem 271, 18100-18106.
37. Mortensen OV, Kristensen AS, Rudnick G, &, Wiborg O, (1999) Molecular cloning, expression and characterization of a bovine serotonin transporter. Brain Res Mol Brain Res 71, 120-126.
38. Jensen LD, Vinther-Jensen T, Kahns S, Sundbye S, &, Jensen PH, (2006) Cellular parkin mutants are soluble under non-stress conditions. Neuroreport 17, 1205-1208.
39. Kleinnijenhuis AJ, Hedegaard C, Lundvig D, Sundbye S, Issinger OG, Jensen ON, &, Jensen PH, (2008) Identification of multiple post-translational modifications in the porcine brain specific p25α. J Neurochem 106, 925-933.
40. Kubo S, Kitami T, Noda S, Shimura H, Uchiyama Y, Askawa S, Minoshima S, Shimizu N, Mizuno Y, &, Hattori N, (2001) Parkin is associated with cellular vesicles. J Neurochem 78, 42-54.
41. Larsen MB, Fjorback AW, &, Wiborg O, (2006) The C-terminus is critical for the functional expression of the human serotonin transporter. Biochemistry 45, 1331-1337.